UK Drug Safety Agency Falsified Vaccine Safety Data For 6 Million

Short link to this page: http://wp.me/pfSi7-1UC

[See also "Japan’s Suspension of Recommendation for Gardasil & Cervarix HPV Vaccines for Women – Caused by Large Numbers of Unexplained Serious Adverse Reactions"]

This world exclusive report by CHS follows the decision by health authorities in Japan to withdraw their recommendation for human papilloma virus [HPV] vaccines because of high levels of serious adverse reactions in Japanese women and girls. 

But in the UK data from over 6000 reports of suspected adverse reactions in British schoolgirls was systematically altered resulting in the Medicines and Healthcare Products Regulatory Agency [MHRA] declaring the vaccine safe when it was not.   With 6 million doses given to nearly 2 million British schoolgirls the MHRA’s actions are serious but benefit British Cervarix vaccine maker GlaxoSmithKline. 98 in 100 adverse drug reactions go unreported: Spontaneous adverse drug reaction reporting vs event monitoring: a comparison: Journal of the Royal Society of Medicine Volume 84 June 1991 341.

In Japan Cervarix and Gardasil HPV vaccines were found to cause substantially higher rates of adverse reactions than other vaccines: Cervix vaccine issues trigger health notice Japan Times Jun 15, 2013 National Kyodo.

One report claims the rate of serious adverse reactions which Japanese women experienced after Cervarix injections are 52 times the rate of those reported after annual influenza vaccines: Urgent Request from Japan: Help Stop HPV Vaccinations July 27, 2013 By Norma Erickson SaneVax, IncJapanese girls will still be able to be vaccinated at no charge, but from now on they will be informed by healthcare providers that the health ministry does not recommend the vaccines.

The UK media fail to report this kind of news affecting millions of British school children and families despite affecting their own families and networks of relatives in the UK.  Journalism is a dying profession.  Don’t buy newspapers or believe TV news reports.  The UK’s BBC has become the British Government’s press office.

British Parents Not Told Their Children Are Not At Risk of Cervical Cancer

The targeted vaccination group of 12-year-old British schoolgirls are at no risk of contracting cervical cancer.  Cervical cancer is an extremely rare disease.  The risk is normally zero up to age 20The risk of serious adverse reactions from the vaccine is therefore infinitely higher.  In the UK the disease is so rare there are just 3 deaths in every 100,000 women of all ages as figures from Cancer Research UK showWhat is worse is that by the time there is any risk for these schoolgirls any effect from the vaccine [if there ever was one] would have worn off yet these young women may then think they are protected and fail to undergo routine screening when they will still need it regardless of the vaccine. 

By the time there is any risk of mortality for these 12 year-old schoolgirls it is extremely low.  The risk of death from cervical cancer in the age range 20-24 is 3 in every million women of that age range.  The disease does not normally affect schoolgirls.  The highest number of deaths occur in women in their late seventies.

How UK Health Officials Tampered With the Adverse Reaction Reporting Systems

In the UK the MHRA’s first interference was to encourage health professional not to report adverse reactions.  This was done in formal advice issued in the name of Chief Executive Professor Sir Kent Woods telling health professionals that reactions can be “psychogenic” – or in simpler terms a figment of 12 year old schoolgirls’ imaginations and nothing to do with the vaccines [see more below for full details].

Next the data from over 6000 reports of suspected adverse reactions was systematically altered resulting in the MHRA declaring the vaccine safe when it was not. 

The third thing the MHRA staff did was to fix the final figures to make the rate of adverse reactions appear lower by substituting the number of doses given for the number of children receiving the vaccine.  Tampering with statistics by basing rates of adverse reactions on doses given reduced the numbers of adverse reactions per child by three times.  This is because each child was to receive three doses of the vaccine.  So whilst 6 million doses may have been given that represented only around one third of that figure in children receiving the vaccine – resulting in the rates of adverse reactions reported being calculated as 300% lower than they were per child. 

In other words if all children received all three doses then the crucial figure was not the number of doses but the number of children who suffered reactions compared to the total number of children.

The MHRA was headed at the time by Chairman Professor Alasdair Breckenridge [retired December 2012] and Professor Sir Kent Woods [MHRA Chief Executive but shortly expected to retire after 10 years service].

Questions For Heads Of UK Drug Regulatory Agency – MHRA

The first question for Professors Breckenridge and Woods is – if Japanese women suffered adverse reactions at a rate 52 times higher for GSK’s Cervarix vaccine than for flu vaccine how can possible adverse reactions just be figments of childrens’ imagination and so are not to be reported by medical professionals? ["psychogenic" was how Woods put it more formally - see his official advice to medical professionals - more below].

Clearly, that cannot be the case. Not only that but Woods and Breckenridge cannot claim to be ignorant of those facts. They must know that is the position. Nearly half of all reports included what the MHRA categorised as “psychogenic” symptoms which the MHRA say are “all in the mind” and could not therefore be caused by the vaccine.  A full list in a spreadsheet to enable further sorting and analysis can be downloaded here: 130728 Single list of all Cervarix Yellow Card Reports or browsed at the end of this article.  

You can also download the MHRA’s own published .pdf analyses listing the symptoms reported broken up into these five groups.  These are the reports used to declare the vaccine safe:

Here are just a few examples of MHRA’s alleged “all in the mind” “psychogenic” reactions by “hysterical schoolgirls”:

  • convulsions [which are serious reactions with risks of serious brain injury];
  • grand mal convulsions;
  • deafness
  • circulatory collapse;
  • acquired colour blindness;
  • head banging;
  • foaming at mouth;
  • transient blindness;
  • transient deafness;

The next question is: who instructed staff of the UK’s Medicines and Healthcare Products Regulatory Agency [MHRA] systematically to tamper with the reporting systems and with data in reports of adverse reactions by medical professionals to Cervarix HPV vaccines given to millions British Schoolgirls from December 2008 to July 2012?

And the next question is who instructed that none of the adverse reaction reports should be followed-up and conditions of the children investigated?  There is little point having drug safety monitoring if the data obtained from it is ignored.  The MHRA hid the conditions in those cases which were reported.

Official Excuses for Withdrawal of GSK’s Cervarix HPV Vaccine Do Not Stand Up

In 2012 GSK’s Cervarix HPV vaccine was replaced by Merck’s Gardasil HPV vaccine.  At the time this was claimed to be a result of competitive tendering.  However it is a requirement that the Department of Health is required to ensure vaccine supply is not from a sole source.  This requirement was made following criticism in the English Parliament and by the UK National Audit Office over problems caused previously by the failure of a sole source of supply of a different vaccine.

Professor Sir Kent Woods Instructs Medical Professionals Not To Report Adverse Reactions.

In advice dated 2nd September 2008 issued by the UK MHRA in Professor Kent Woods name Professor Woods primed health professionals to expect the most common adverse reactions would be “psychogenic”.  Professor Woods then advised medical professionals not to report an adverse reaction if it “may” be psychogenic. 

“Psychogenic” means that the symptom of the adverse reaction is to be treated as “all in the minds” of the British schoolgirls receiving GSK’s Cervarix vaccine – that is: the result of emotional or mental stress from the administration of the vaccine.

In other words – and feminists please take note – the male dominated MHRA was telling medical professionals to dismiss adverse reactions in schoolgirls because women are prone to that sort of thing – you know – women are silly, emotional and prone to hysteria and mass hysteria.

This advice was not only counterproductive but unscientific and improper from a drug safety perspective.  Professors Woods and Breckenridge must know that. 

Adverse reactions to all pharmaceuticals are heavily under-reported.  Because of that medical professionals are constantly and generally encouraged to file adverse reaction reports to improve drug safety monitoring. Professor Woods’ advice was encouraging them not to.

An adverse reaction reporting system relies on the spectrum of adverse events to be reported so that it is possible to identify the “signal” of a previously unidentified adverse drug reaction against the background of known adverse reactions and reports. 

By encouraging medical professionals to expect and then not to report suspected “psychogenic” reactions would result in reactions which were not psychogenic being identified as such and which would then not be reported following Professor Kent Woods’ advice.  This would also make drug safety monitoring much less effective because if there were truly any “psychogenic” reactions, then subsequent analyses of the data could assist to identify which were likely to have been and which were not so likely or were not.  But the less data one has makes the task more difficult.

MHRA Systematically Tampered with 6000 reports of Adverse Reactions To Declare The Vaccine Safe

From April 2008 up to 31st July 2012, the MHRA received a total of 6213 reports of suspected adverse reactions documenting 14,300 symptoms or 2 1/2 symptoms per report.  Nurses contributed more than two-thirds of all reports.  Over 6 million doses of the vaccine were administered.

The way the reports of suspected adverse reactions to GSK’s Cervarix vaccine were tampered with was to ensure the underlying conditions indicated by the reported symptoms could not be identified.  In addition, no clinical follow-up was carried out on any Cervarix Yellow Card report of a suspected adverse reaction. 

To diagnose an individual it is essential to consider all symptoms suffered by that individual and carry out a clinical assessment on a case-by-case basis.  For example, how do you know if you might have flu?  If you have fever, cough, headache, aching muscles and tiredness then you may have flu.

What the MHRA did was to carry out a paper analysis of the Yellow Card reports.  They separated out the symptoms reported for each individual so that it would be impossible for anyone to identify the underlying conditions each individual suffered.  SOURCE: MHRA 29 July 2010 “Suspected Adverse Reaction Analysis”

Here are the 5 categories each symptom was separated into:

A. Injection-site reactions
B. Allergic reactions
C. ‘Psychogenic’ events
D. ‘Other recognised’ reactions
E. not currently recognised

So if we consider by analogy a disease most people know about, flu, if this approach was applied to infectious disease reports each symptom would be split up and put into one or more of these categories.  As the symptoms are no longer linked together it is impossible to say whether anyone was suffering from ‘flu or any other disease.  There would be no way of telling.

Thus, the MHRA set about hiding the numbers and types of suspected ADRs suffered by British schoolchildren. This was not a conspiracy but fact – that is what the MHRA did.

If this approach were adopted to reporting infectious diseases generally the public could have no idea which diseases are present in the population at any time.  There can be numerous infections diseases circulating simultaneously.

For example, a symptom of encephalitis is headache – in the period Sept 08 to 29 July 2010  information from MHRA recorded that in 4703 Yellow Card reports there were 848 reports  which included headache as one of the reported symptoms and  which might therefore be of encephalitis. A “quick and dirty” analysis of the MHRA data issued at that time shows that of just 5 of the 32 symptoms of encephalitis at least 2300 reports include at least one symptom of encephalitis.

But this is what the MHRA said having carried out no clinical investigation or analysis of any of the Yellow Card reports:-

The four cases of encephalitis reported so far, amongst the number of girls immunised, do not exceed  the numbers normally expected in the absence of vaccination. There is therefore no suggestion at present that the vaccine can cause encephalitis.”

SOURCE: MHRA 29 July 2010 “Suspected Adverse Reaction Analysis

This shows

  • MHRA only recorded a report as suspected encephalitis if those specific words appear on the Yellow Card report
  • and confirms MHRA did not consider what underlying conditions are indicated by the symptoms reported on the Yellow Cards

Most reports were by school nurses who are likely only to report the symptoms and not diagnose underlying conditions.

School Head Teachers & Governors

It is obvious from these figures that UK parents are obliged under their Children Act 1989 legal duties to refuse consent.  This also puts head teachers and school governors in a remarkable position for putting children at risk by allowing these vaccination programmes to take place on school premises. Under English law they stand legally in “loco parentis” – in the place of the parents whilst children are under their care in school.

School Nurses & Other Medical Professionals.

Obviously medical practitioners bear a heavy duty of disclosure to obtain informed consent but they are not fulfilling it.  Additionally, it is obvious that anyone proposing to have this vaccine needs to be screened for 1) pre-existing medical conditions putting them at risk and 2) risk of adverse reactions based on prior clinical history.  That is not being done.

Properly informed consent is not being obtained – which legally can give rise to claims for “battery” – not simply negligence and easier to prove.

Parents are being told their 13-year-old girls may be given the vaccine even if the parents refuse consent. Girls of this age might be subject to pressure to persuade them even if parents have refused consent. There are reasons why this may not be lawful under “Gillick competence”.

ANNEX I

LIST OF MHRA REPORTED SYMPTOMS OF ADVERSE REACTIONS TO GSK’S CERVARIX HPV VACCINE – Source MHRA “Suspected Adverse Reaction Analysis” 29th July 2010 

[Also downloadable as a spreadsheet from here 130728 Single list of all Cervarix Yellow Card Reports]
System Organ Class Category A to E Reported event (Preferred Term)

Number of cases

A. Injection-site reactions Pain in extremity 485

485

A. Injection-site reactions Injection site swelling 113

113

A. Injection-site reactions Oedema peripheral 109

109

A. Injection-site reactions Limb discomfort 106

106

A. Injection-site reactions Hypoaesthesia 105

105

A. Injection-site reactions Injection site erythema 85

85

A. Injection-site reactions Injection site pain 81

81

A. Injection-site reactions Erythema 45

45

A. Injection-site reactions Paraesthesia 37

37

A. Injection-site reactions Skin discolouration 33

33

A. Injection-site reactions Injection site rash 32

32

A. Injection-site reactions Injection site mass 29

29

A. Injection-site reactions Injection site reaction 26

26

A. Injection-site reactions Pain 23

23

A. Injection-site reactions Contusion 21

21

A. Injection-site reactions Musculoskeletal stiffness 21

21

A. Injection-site reactions Peripheral coldness 20

20

A. Injection-site reactions Local reaction 19

19

A. Injection-site reactions Injection site inflammation 18

18

A. Injection-site reactions Injection site warmth 18

18

A. Injection-site reactions Pain in extremity 16

16

A. Injection-site reactions Local swelling 15

15

A. Injection-site reactions Sensation of heaviness 15

15

A. Injection-site reactions Injection site haematoma 12

12

A. Injection-site reactions Injection site pruritus 11

11

A. Injection-site reactions Rash macular 10

10

A. Injection-site reactions Oedema peripheral 9

9

A. Injection-site reactions Feeling cold 8

8

A. Injection-site reactions Injection site induration 8

8

A. Injection-site reactions Injection site nodule 8

8

A. Injection-site reactions Livedo reticularis 8

8

A. Injection-site reactions Swelling 8

8

A. Injection-site reactions Injection site anaesthesia 6

6

A. Injection-site reactions Injection site swelling 6

6

A. Injection-site reactions Muscular weakness 6

6

A. Injection-site reactions Myalgia 6

6

A. Injection-site reactions Neck pain 6

6

A. Injection-site reactions Pain 6

6

A. Injection-site reactions Rash 6

6

A. Injection-site reactions Erythema 5

5

A. Injection-site reactions Feeling hot 5

5

A. Injection-site reactions Injection site erythema 5

5

A. Injection-site reactions Pruritus 5

5

A. Injection-site reactions Cyanosis 4

4

A. Injection-site reactions Feeling abnormal 4

4

A. Injection-site reactions Injection site infection 4

4

A. Injection-site reactions Musculoskeletal stiffness 4

4

A. Injection-site reactions Pallor 4

4

A. Injection-site reactions Sensory disturbance 4

4

A. Injection-site reactions Tenderness 4

4

A. Injection-site reactions Asthenia 3

3

A. Injection-site reactions Feeling hot 3

3

A. Injection-site reactions Inflammation 3

3

A. Injection-site reactions Injection site discharge 3

3

A. Injection-site reactions Injection site discolouration 3

3

A. Injection-site reactions Injection site irritation 3

3

A. Injection-site reactions Injection site reaction 3

3

A. Injection-site reactions Injection site urticaria 3

3

A. Injection-site reactions Injection site vesicles 3

3

A. Injection-site reactions Limb immobilisation 3

3

A. Injection-site reactions Musculoskeletal pain 3

3

A. Injection-site reactions Poor peripheral circulation 3

3

A. Injection-site reactions Sensory loss 3

3

A. Injection-site reactions Skin warm 3

3

A. Injection-site reactions Dry skin 2

2

A. Injection-site reactions Grip strength decreased 2

2

A. Injection-site reactions Hypoaesthesia 2

2

A. Injection-site reactions Injected limb mobility decreased 2

2

A. Injection-site reactions Injection site cellulitis 2

2

A. Injection-site reactions Injection site coldness 2

2

A. Injection-site reactions Injection site discolouration 2

2

A. Injection-site reactions Injection site mass 2

2

A. Injection-site reactions Injection site pain 2

2

A. Injection-site reactions Peripheral coldness 2

2

A. Injection-site reactions Pruritus 2

2

A. Injection-site reactions Sensory loss 2

2

A. Injection-site reactions Skin discolouration 2

2

A. Injection-site reactions Skin reaction 2

2

A. Injection-site reactions Skin reaction 2

2

A. Injection-site reactions Tenderness 2

2

A. Injection-site reactions Blister 1

1

A. Injection-site reactions Complex regional pain syndrome 1

1

A. Injection-site reactions Extensive swelling of vaccinated limb 1

1

A. Injection-site reactions Hyperaesthesia 1

1

A. Injection-site reactions Hyperaesthesia 1

1

A. Injection-site reactions Hypokinesia 1

1

A. Injection-site reactions Hypokinesia 1

1

A. Injection-site reactions Immobile 1

1

A. Injection-site reactions Impetigo 1

1

A. Injection-site reactions Injection site abscess 1

1

A. Injection-site reactions Injection site anaesthesia 1

1

A. Injection-site reactions Injection site coldness 1

1

A. Injection-site reactions Injection site discomfort 1

1

A. Injection-site reactions Injection site haematoma 1

1

A. Injection-site reactions Injection site haemorrhage 1

1

A. Injection-site reactions Injection site haemorrhage 1

1

A. Injection-site reactions Injection site joint movement impairment 1

1

A. Injection-site reactions Injection site joint pain 1

1

A. Injection-site reactions Injection site movement impairment 1

1

A. Injection-site reactions Injection site movement impairment 1

1

A. Injection-site reactions Injection site papule 1

1

A. Injection-site reactions Injection site paraesthesia 1

1

A. Injection-site reactions Injection site rash 1

1

A. Injection-site reactions Injection site scab 1

1

A. Injection-site reactions Joint swelling 1

1

A. Injection-site reactions Limb immobilisation 1

1

A. Injection-site reactions Local reaction 1

1

A. Injection-site reactions Local swelling 1

1

A. Injection-site reactions Lymphoedema 1

1

A. Injection-site reactions Mass 1

1

A. Injection-site reactions Mobility decreased 1

1

A. Injection-site reactions Muscle rigidity 1

1

A. Injection-site reactions Muscle spasms 1

1

A. Injection-site reactions Muscle tightness 1

1

A. Injection-site reactions Musculoskeletal pain 1

1

A. Injection-site reactions Nausea 1

1

A. Injection-site reactions Nodule 1

1

A. Injection-site reactions Pain of skin 1

1

A. Injection-site reactions Paraesthesia 1

1

A. Injection-site reactions Peripheral vascular disorder 1

1

A. Injection-site reactions Rash 1

1

A. Injection-site reactions Rash maculo-papular 1

1

A. Injection-site reactions Rash pruritic 1

1

A. Injection-site reactions Scab 1

1

A. Injection-site reactions Sensation of heaviness 1

1

A. Injection-site reactions Sensation of pressure 1

1

A. Injection-site reactions Tremor 1

1

A. Injection-site reactions Urticaria 1

1

A. Injection-site reactions Urticaria 1

1

B. Allergic reactions Rash 130

130

B. Allergic reactions Urticaria 89

89

B. Allergic reactions Pruritus 60

60

B. Allergic reactions Erythema 47

47

B. Allergic reactions Swelling face 42

42

B. Allergic reactions Anaphylactic reaction 41

41

B. Allergic reactions Dyspnoea 33

33

B. Allergic reactions Rash generalised 31

31

B. Allergic reactions Rash pruritic 31

31

B. Allergic reactions Oedema peripheral 29

29

B. Allergic reactions Lip swelling 26

26

B. Allergic reactions Rash macular 24

24

B. Allergic reactions Dizziness 23

23

B. Allergic reactions Hypersensitivity 22

22

B. Allergic reactions Eye swelling 18

18

B. Allergic reactions Paraesthesia oral 17

17

B. Allergic reactions Malaise 15

15

B. Allergic reactions Throat tightness 14

14

B. Allergic reactions Rash 13

13

B. Allergic reactions Swollen tongue 13

13

B. Allergic reactions Chest discomfort 11

11

B. Allergic reactions Rash erythematous 11

11

B. Allergic reactions Feeling hot 9

9

B. Allergic reactions Flushing 9

9

B. Allergic reactions Pruritus generalised 9

9

B. Allergic reactions Dermatitis allergic 8

8

B. Allergic reactions Pallor 8

8

B. Allergic reactions Pharyngeal oedema 8

8

B. Allergic reactions Urticaria 8

8

B. Allergic reactions Fatigue 7

7

B. Allergic reactions Oropharyngeal pain 7

7

B. Allergic reactions Paraesthesia 7

7

B. Allergic reactions Angioedema 6

6

B. Allergic reactions Dysphagia 6

6

B. Allergic reactions Headache 6

6

B. Allergic reactions Inflammation 6

6

B. Allergic reactions Pyrexia 6

6

B. Allergic reactions Throat irritation 6

6

B. Allergic reactions Blister 5

5

B. Allergic reactions Dyspnoea 5

5

B. Allergic reactions Hyperventilation 5

5

B. Allergic reactions Hypoaesthesia oral 5

5

B. Allergic reactions Vomiting 5

5

B. Allergic reactions Wheezing 5

5

B. Allergic reactions Anaphylactic shock 4

4

B. Allergic reactions Eyelid oedema 4

4

B. Allergic reactions Hypersensitivity 4

4

B. Allergic reactions Hypoaesthesia 4

4

B. Allergic reactions Local swelling 4

4

B. Allergic reactions Nausea 4

4

B. Allergic reactions Pain in extremity 4

4

B. Allergic reactions Dermatitis allergic 3

3

B. Allergic reactions Erythema 3

3

B. Allergic reactions Eye pruritus 3

3

B. Allergic reactions Eyelid oedema 3

3

B. Allergic reactions Hyperhidrosis 3

3

B. Allergic reactions Laryngeal oedema 3

3

B. Allergic reactions Limb discomfort 3

3

B. Allergic reactions Nasopharyngitis 3

3

B. Allergic reactions Ocular hyperaemia 3

3

B. Allergic reactions Pain 3

3

B. Allergic reactions Petechiae 3

3

B. Allergic reactions Rash erythematous 3

3

B. Allergic reactions Rash macular 3

3

B. Allergic reactions Rash maculo-papular 3

3

B. Allergic reactions Rash pruritic 3

3

B. Allergic reactions Skin irritation 3

3

B. Allergic reactions Skin reaction 3

3

B. Allergic reactions Somnolence 3

3

B. Allergic reactions Swelling 3

3

B. Allergic reactions Vision blurred 3

3

B. Allergic reactions Abdominal pain 2

2

B. Allergic reactions Abdominal pain upper 2

2

B. Allergic reactions Anaphylactic reaction 2

2

B. Allergic reactions Blister 2

2

B. Allergic reactions Body temperature increased 2

2

B. Allergic reactions Cold sweat 2

2

B. Allergic reactions Dermatitis contact 2

2

B. Allergic reactions Dizziness 2

2

B. Allergic reactions Face oedema 2

2

B. Allergic reactions Feeling cold 2

2

B. Allergic reactions Heart rate increased 2

2

B. Allergic reactions Heart rate irregular 2

2

B. Allergic reactions Heat rash 2

2

B. Allergic reactions Lip swelling 2

2

B. Allergic reactions Peripheral coldness 2

2

B. Allergic reactions Pharyngeal oedema 2

2

B. Allergic reactions Pruritus 2

2

B. Allergic reactions Rash generalised 2

2

B. Allergic reactions Skin discolouration 2

2

B. Allergic reactions Skin disorder 2

2

B. Allergic reactions Swollen tongue 2

2

B. Allergic reactions Tachycardia 2

2

B. Allergic reactions Type i hypersensitivity 2

2

B. Allergic reactions Anaphylactoid reaction 1

1

B. Allergic reactions Asthenia 1

1

B. Allergic reactions Asthenopia 1

1

B. Allergic reactions Asthma 1

1

B. Allergic reactions Back pain 1

1

B. Allergic reactions Breath sounds abnormal 1

1

B. Allergic reactions Bronchospasm 1

1

B. Allergic reactions Chest pain 1

1

B. Allergic reactions Chills 1

1

B. Allergic reactions Condition aggravated 1

1

B. Allergic reactions Confusional state 1

1

B. Allergic reactions Conjunctival hyperaemia 1

1

B. Allergic reactions Contusion 1

1

B. Allergic reactions Convulsion 1

1

B. Allergic reactions Cough 1

1

B. Allergic reactions Dermatitis 1

1

B. Allergic reactions Dry throat 1

1

B. Allergic reactions Dysphagia 1

1

B. Allergic reactions Eczema 1

1

B. Allergic reactions Eczema 1

1

B. Allergic reactions Eyelid disorder 1

1

B. Allergic reactions Eyes sunken 1

1

B. Allergic reactions Fatigue 1

1

B. Allergic reactions Feeling abnormal 1

1

B. Allergic reactions Feeling hot 1

1

B. Allergic reactions Feeling jittery 1

1

B. Allergic reactions Generalised erythema 1

1

B. Allergic reactions Gingival swelling 1

1

B. Allergic reactions Headache 1

1

B. Allergic reactions Hypersomnia 1

1

B. Allergic reactions Hypertension 1

1

B. Allergic reactions Hypoventilation 1

1

B. Allergic reactions Increased bronchial secretion 1

1

B. Allergic reactions Infusion site swelling 1

1

B. Allergic reactions Laryngeal oedema 1

1

B. Allergic reactions Lethargy 1

1

B. Allergic reactions Lip blister 1

1

B. Allergic reactions Lip ulceration 1

1

B. Allergic reactions Local reaction 1

1

B. Allergic reactions Loss of consciousness 1

1

B. Allergic reactions Migraine 1

1

B. Allergic reactions Muscle tightness 1

1

B. Allergic reactions Musculoskeletal stiffness 1

1

B. Allergic reactions Myalgia 1

1

B. Allergic reactions Mydriasis 1

1

B. Allergic reactions Nausea 1

1

B. Allergic reactions Neck pain 1

1

B. Allergic reactions Oedema mouth 1

1

B. Allergic reactions Oedema mouth 1

1

B. Allergic reactions Oesophageal discomfort 1

1

B. Allergic reactions Oral discomfort 1

1

B. Allergic reactions Oral pain 1

1

B. Allergic reactions Palpitations 1

1

B. Allergic reactions Panic reaction 1

1

B. Allergic reactions Paraesthesia oral 1

1

B. Allergic reactions Periorbital oedema 1

1

B. Allergic reactions Photophobia 1

1

B. Allergic reactions Piloerection 1

1

B. Allergic reactions Pulse absent 1

1

B. Allergic reactions Purpura 1

1

B. Allergic reactions Pyrexia 1

1

B. Allergic reactions Rash follicular 1

1

B. Allergic reactions Rash papular 1

1

B. Allergic reactions Respiratory rate increased 1

1

B. Allergic reactions Sensation of foreign body 1

1

B. Allergic reactions Sneezing 1

1

B. Allergic reactions Somnolence 1

1

B. Allergic reactions Speech disorder 1

1

B. Allergic reactions Stridor 1

1

B. Allergic reactions Swelling 1

1

B. Allergic reactions Swelling face 1

1

B. Allergic reactions Syncope 1

1

B. Allergic reactions Systemic lupus erythematosus rash 1

1

B. Allergic reactions Tenderness 1

1

B. Allergic reactions Thirst 1

1

B. Allergic reactions Throat irritation 1

1

B. Allergic reactions Throat tightness 1

1

B. Allergic reactions Tremor 1

1

B. Allergic reactions Type IV hypersensitivity reaction 1

1

B. Allergic reactions Urticaria pigmentosa 1

1

B. Allergic reactions Visual impairment 1

1

B. Allergic reactions Vomiting 1

1

C. ‘Psychogenic’ events Dizziness 327

327

C. ‘Psychogenic’ events Syncope 296

296

C. ‘Psychogenic’ events Nausea 151

151

C. ‘Psychogenic’ events Headache 109

109

C. ‘Psychogenic’ events Pallor 108

108

C. ‘Psychogenic’ events Vomiting 77

77

C. ‘Psychogenic’ events Malaise 74

74

C. ‘Psychogenic’ events Tremor 61

61

C. ‘Psychogenic’ events Vision blurred 46

46

C. ‘Psychogenic’ events Feeling hot 45

45

C. ‘Psychogenic’ events Flushing 40

40

C. ‘Psychogenic’ events Cold sweat 35

35

C. ‘Psychogenic’ events Syncope 27

27

C. ‘Psychogenic’ events Hyperhidrosis 25

25

C. ‘Psychogenic’ events Presyncope 23

23

C. ‘Psychogenic’ events Hyperventilation 21

21

C. ‘Psychogenic’ events Loss of consciousness 19

19

C. ‘Psychogenic’ events Dyspnoea 18

18

C. ‘Psychogenic’ events Paraesthesia 18

18

C. ‘Psychogenic’ events Chills 17

17

C. ‘Psychogenic’ events Convulsion 17

17

C. ‘Psychogenic’ events Pyrexia 16

16

C. ‘Psychogenic’ events Somnolence 16

16

C. ‘Psychogenic’ events Dizziness 15

15

C. ‘Psychogenic’ events Fatigue 15

15

C. ‘Psychogenic’ events Heart rate increased 14

14

C. ‘Psychogenic’ events Unresponsive to stimuli 14

14

C. ‘Psychogenic’ events Muscle twitching 13

13

C. ‘Psychogenic’ events Rash 13

13

C. ‘Psychogenic’ events Asthenia 12

12

C. ‘Psychogenic’ events Feeling cold 12

12

C. ‘Psychogenic’ events Hypoaesthesia 12

12

C. ‘Psychogenic’ events Panic attack 12

12

C. ‘Psychogenic’ events Chest discomfort 11

11

C. ‘Psychogenic’ events Dyskinesia 11

11

C. ‘Psychogenic’ events Eye rolling 11

11

C. ‘Psychogenic’ events Tachycardia 11

11

C. ‘Psychogenic’ events Tearfulness 11

11

C. ‘Psychogenic’ events Nervousness 10

10

C. ‘Psychogenic’ events Erythema 9

9

C. ‘Psychogenic’ events Headache 9

9

C. ‘Psychogenic’ events Rash macular 9

9

C. ‘Psychogenic’ events Abdominal pain 8

8

C. ‘Psychogenic’ events Chest pain 8

8

C. ‘Psychogenic’ events Peripheral coldness 8

8

C. ‘Psychogenic’ events Abdominal pain upper 7

7

C. ‘Psychogenic’ events Anxiety 7

7

C. ‘Psychogenic’ events Fall 7

7

C. ‘Psychogenic’ events Hypotension 7

7

C. ‘Psychogenic’ events Lethargy 7

7

C. ‘Psychogenic’ events Muscular weakness 7

7

C. ‘Psychogenic’ events Photophobia 7

7

C. ‘Psychogenic’ events Visual impairment 7

7

C. ‘Psychogenic’ events Confusional state 6

6

C. ‘Psychogenic’ events Deafness 6

6

C. ‘Psychogenic’ events Feeling of body temperature change 6

6

C. ‘Psychogenic’ events Muscle rigidity 6

6

C. ‘Psychogenic’ events Musculoskeletal stiffness 6

6

C. ‘Psychogenic’ events Mydriasis 6

6

C. ‘Psychogenic’ events Nasopharyngitis 6

6

C. ‘Psychogenic’ events Throat tightness 6

6

C. ‘Psychogenic’ events Dizziness postural 5

5

C. ‘Psychogenic’ events Dysgeusia 5

5

C. ‘Psychogenic’ events Feeling abnormal 5

5

C. ‘Psychogenic’ events Pallor 5

5

C. ‘Psychogenic’ events Skin discolouration 5

5

C. ‘Psychogenic’ events Urticaria 5

5

C. ‘Psychogenic’ events Abdominal discomfort 4

4

C. ‘Psychogenic’ events Blindness transient 4

4

C. ‘Psychogenic’ events Body temperature increased 4

4

C. ‘Psychogenic’ events Decreased appetite 4

4

C. ‘Psychogenic’ events Hot flush 4

4

C. ‘Psychogenic’ events Migraine 4

4

C. ‘Psychogenic’ events Muscle spasms 4

4

C. ‘Psychogenic’ events Pulse abnormal 4

4

C. ‘Psychogenic’ events Respiratory rate increased 4

4

C. ‘Psychogenic’ events Tinnitus 4

4

C. ‘Psychogenic’ events Urinary incontinence 4

4

C. ‘Psychogenic’ events Vomiting 4

4

C. ‘Psychogenic’ events Abasia 3

3

C. ‘Psychogenic’ events Agitation 3

3

C. ‘Psychogenic’ events Balance disorder 3

3

C. ‘Psychogenic’ events Blindness 3

3

C. ‘Psychogenic’ events Blood pressure decreased 3

3

C. ‘Psychogenic’ events Cyanosis 3

3

C. ‘Psychogenic’ events Disorientation 3

3

C. ‘Psychogenic’ events Disturbance in attention 3

3

C. ‘Psychogenic’ events Dyspnoea 3

3

C. ‘Psychogenic’ events Dysstasia 3

3

C. ‘Psychogenic’ events Emotional disorder 3

3

C. ‘Psychogenic’ events Feeling drunk 3

3

C. ‘Psychogenic’ events Hearing impaired 3

3

C. ‘Psychogenic’ events Heart rate irregular 3

3

C. ‘Psychogenic’ events Hypoventilation 3

3

C. ‘Psychogenic’ events Nausea 3

3

C. ‘Psychogenic’ events Pain 3

3

C. ‘Psychogenic’ events Pain in extremity 3

3

C. ‘Psychogenic’ events Panic reaction 3

3

C. ‘Psychogenic’ events Rash 3

3

C. ‘Psychogenic’ events Sensory loss 3

3

C. ‘Psychogenic’ events Somnolence 3

3

C. ‘Psychogenic’ events Throat irritation 3

3

C. ‘Psychogenic’ events Vertigo 3

3

C. ‘Psychogenic’ events Amnesia 2

2

C. ‘Psychogenic’ events Blood pressure increased 2

2

C. ‘Psychogenic’ events Body temperature decreased 2

2

C. ‘Psychogenic’ events Bradycardia 2

2

C. ‘Psychogenic’ events Circulatory collapse 2

2

C. ‘Psychogenic’ events Colour blindness acquired 2

2

C. ‘Psychogenic’ events Consciousness fluctuating 2

2

C. ‘Psychogenic’ events Diplopia 2

2

C. ‘Psychogenic’ events Dry mouth 2

2

C. ‘Psychogenic’ events Dry throat 2

2

C. ‘Psychogenic’ events Dysarthria 2

2

C. ‘Psychogenic’ events Dysphagia 2

2

C. ‘Psychogenic’ events Emotional distress 2

2

C. ‘Psychogenic’ events Heart rate decreased 2

2

C. ‘Psychogenic’ events Heart rate increased 2

2

C. ‘Psychogenic’ events Hypertension 2

2

C. ‘Psychogenic’ events Hyperventilation 2

2

C. ‘Psychogenic’ events Hypoacusis 2

2

C. ‘Psychogenic’ events Malaise 2

2

C. ‘Psychogenic’ events Muscular weakness 2

2

C. ‘Psychogenic’ events Myalgia 2

2

C. ‘Psychogenic’ events Neck pain 2

2

C. ‘Psychogenic’ events Oropharyngeal pain 2

2

C. ‘Psychogenic’ events Paraesthesia oral 2

2

C. ‘Psychogenic’ events Presyncope 2

2

C. ‘Psychogenic’ events Procedural dizziness 2

2

C. ‘Psychogenic’ events Pruritus 2

2

C. ‘Psychogenic’ events Pulse pressure decreased 2

2

C. ‘Psychogenic’ events Pupil fixed 2

2

C. ‘Psychogenic’ events Rash generalised 2

2

C. ‘Psychogenic’ events Retching 2

2

C. ‘Psychogenic’ events Salivary hypersecretion 2

2

C. ‘Psychogenic’ events Shock 2

2

C. ‘Psychogenic’ events Vision blurred 2

2

C. ‘Psychogenic’ events Abdominal discomfort 1

1

C. ‘Psychogenic’ events Abdominal distension 1

1

C. ‘Psychogenic’ events Abdominal pain 1

1

C. ‘Psychogenic’ events Abnormal behaviour 1

1

C. ‘Psychogenic’ events Altered state of consciousness 1

1

C. ‘Psychogenic’ events Aphasia 1

1

C. ‘Psychogenic’ events Asthenia 1

1

C. ‘Psychogenic’ events Asthma 1

1

C. ‘Psychogenic’ events Back pain 1

1

C. ‘Psychogenic’ events Blindness transient 1

1

C. ‘Psychogenic’ events Blood pressure increased 1

1

C. ‘Psychogenic’ events Blood pressure systolic decreased 1

1

C. ‘Psychogenic’ events Body temperature decreased 1

1

C. ‘Psychogenic’ events Bruxism 1

1

C. ‘Psychogenic’ events Burning sensation 1

1

C. ‘Psychogenic’ events Chills 1

1

C. ‘Psychogenic’ events Condition aggravated 1

1

C. ‘Psychogenic’ events Convulsion 1

1

C. ‘Psychogenic’ events Cough 1

1

C. ‘Psychogenic’ events Deafness transitory 1

1

C. ‘Psychogenic’ events Depressed level of consciousness 1

1

C. ‘Psychogenic’ events Discomfort 1

1

C. ‘Psychogenic’ events Dissociation 1

1

C. ‘Psychogenic’ events Disturbance in attention 1

1

C. ‘Psychogenic’ events Dry mouth 1

1

C. ‘Psychogenic’ events Ear discomfort 1

1

C. ‘Psychogenic’ events Ear pain 1

1

C. ‘Psychogenic’ events Epistaxis 1

1

C. ‘Psychogenic’ events Eye pain 1

1

C. ‘Psychogenic’ events Eyelid oedema 1

1

C. ‘Psychogenic’ events Face injury 1

1

C. ‘Psychogenic’ events Facial spasm 1

1

C. ‘Psychogenic’ events Fatigue 1

1

C. ‘Psychogenic’ events Fear 1

1

C. ‘Psychogenic’ events Feeling of despair 1

1

C. ‘Psychogenic’ events Foaming at mouth 1

1

C. ‘Psychogenic’ events Gait disturbance 1

1

C. ‘Psychogenic’ events Grand mal convulsion 1

1

C. ‘Psychogenic’ events Grip strength decreased 1

1

C. ‘Psychogenic’ events Head banging 1

1

C. ‘Psychogenic’ events Head discomfort 1

1

C. ‘Psychogenic’ events Heart rate irregular 1

1

C. ‘Psychogenic’ events Heat rash 1

1

C. ‘Psychogenic’ events Hemiparesis 1

1

C. ‘Psychogenic’ events Hot flush 1

1

C. ‘Psychogenic’ events Hyperhidrosis 1

1

C. ‘Psychogenic’ events Hypersomnia 1

1

C. ‘Psychogenic’ events Hypoaesthesia 1

1

C. ‘Psychogenic’ events Hypoaesthesia facial 1

1

C. ‘Psychogenic’ events Hypokinesia 1

1

C. ‘Psychogenic’ events Hypotonia 1

1

C. ‘Psychogenic’ events Incontinence 1

1

C. ‘Psychogenic’ events Lip swelling 1

1

C. ‘Psychogenic’ events Livedo reticularis 1

1

C. ‘Psychogenic’ events Migraine 1

1

C. ‘Psychogenic’ events Muscle contracture 1

1

C. ‘Psychogenic’ events Myoclonus 1

1

C. ‘Psychogenic’ events Nervous system disorder 1

1

C. ‘Psychogenic’ events Oral discomfort 1

1

C. ‘Psychogenic’ events Palpitations 1

1

C. ‘Psychogenic’ events Paraesthesia 1

1

C. ‘Psychogenic’ events Peripheral circulatory failure 1

1

C. ‘Psychogenic’ events Pharyngeal oedema 1

1

C. ‘Psychogenic’ events Photophobia 1

1

C. ‘Psychogenic’ events Poor peripheral circulation 1

1

C. ‘Psychogenic’ events Pruritus 1

1

C. ‘Psychogenic’ events Psychomotor hyperactivity 1

1

C. ‘Psychogenic’ events Pyrexia 1

1

C. ‘Psychogenic’ events Respiratory arrest 1

1

C. ‘Psychogenic’ events Respiratory rate decreased 1

1

C. ‘Psychogenic’ events Seizure anoxic 1

1

C. ‘Psychogenic’ events Sensation of heaviness 1

1

C. ‘Psychogenic’ events Sensory loss 1

1

C. ‘Psychogenic’ events Sinus tachycardia 1

1

C. ‘Psychogenic’ events Sleep attacks 1

1

C. ‘Psychogenic’ events Sudden onset of sleep 1

1

C. ‘Psychogenic’ events Tachypnoea 1

1

C. ‘Psychogenic’ events Tremor 1

1

C. ‘Psychogenic’ events Urticaria 1

1

C. ‘Psychogenic’ events Visual impairment 1

1

D. ‘Other recognised’ reactions Nausea 631

631

D. ‘Other recognised’ reactions Headache 629

629

D. ‘Other recognised’ reactions Dizziness 625

625

D. ‘Other recognised’ reactions Vomiting 260

260

D. ‘Other recognised’ reactions Malaise 220

220

D. ‘Other recognised’ reactions Fatigue 216

216

D. ‘Other recognised’ reactions Pyrexia 175

175

D. ‘Other recognised’ reactions Abdominal pain 69

69

D. ‘Other recognised’ reactions Diarrhoea 55

55

D. ‘Other recognised’ reactions Abdominal pain upper 54

54

D. ‘Other recognised’ reactions Myalgia 49

49

D. ‘Other recognised’ reactions Lethargy 48

48

D. ‘Other recognised’ reactions Feeling hot 43

43

D. ‘Other recognised’ reactions Body temperature increased 36

36

D. ‘Other recognised’ reactions Pain 34

34

D. ‘Other recognised’ reactions Headache 30

30

D. ‘Other recognised’ reactions Influenza like illness 28

28

D. ‘Other recognised’ reactions Nausea 28

28

D. ‘Other recognised’ reactions Oropharyngeal pain 28

28

D. ‘Other recognised’ reactions Arthralgia 25

25

D. ‘Other recognised’ reactions Malaise 25

25

D. ‘Other recognised’ reactions Pyrexia 24

24

D. ‘Other recognised’ reactions Pallor 22

22

D. ‘Other recognised’ reactions Somnolence 22

22

D. ‘Other recognised’ reactions Asthenia 21

21

D. ‘Other recognised’ reactions Chills 21

21

D. ‘Other recognised’ reactions Pain in extremity 21

21

D. ‘Other recognised’ reactions Rash 21

21

Musculoskeletal and connective tissue disorders D. ‘Other recognised’ reactions Arthralgia 20

20

D. ‘Other recognised’ reactions Lymphadenopathy 18

18

D. ‘Other recognised’ reactions Vomiting 16

16

D. ‘Other recognised’ reactions Abdominal discomfort 15

15

D. ‘Other recognised’ reactions Dizziness 15

15

D. ‘Other recognised’ reactions Flushing 14

14

D. ‘Other recognised’ reactions Paraesthesia 14

14

D. ‘Other recognised’ reactions Fatigue 12

12

D. ‘Other recognised’ reactions Tremor 12

12

D. ‘Other recognised’ reactions Pruritus 11

11

D. ‘Other recognised’ reactions Decreased appetite 10

10

D. ‘Other recognised’ reactions Abdominal pain 8

8

D. ‘Other recognised’ reactions Neck pain 8

8

D. ‘Other recognised’ reactions Feeling cold 7

7

D. ‘Other recognised’ reactions Back pain 6

6

D. ‘Other recognised’ reactions Cough 6

6

D. ‘Other recognised’ reactions Hyperhidrosis 6

6

D. ‘Other recognised’ reactions Hypoaesthesia 6

6

D. ‘Other recognised’ reactions Lethargy 6

6

D. ‘Other recognised’ reactions Musculoskeletal stiffness 6

6

D. ‘Other recognised’ reactions Nasopharyngitis 6

6

D. ‘Other recognised’ reactions Abdominal pain upper 5

5

D. ‘Other recognised’ reactions Asthenia 4

4

D. ‘Other recognised’ reactions Body temperature increased 4

4

D. ‘Other recognised’ reactions Erythema 4

4

D. ‘Other recognised’ reactions Feeling of body temperature change 4

4

D. ‘Other recognised’ reactions Migraine 4

4

D. ‘Other recognised’ reactions Myalgia 4

4

D. ‘Other recognised’ reactions Nervousness 4

4

D. ‘Other recognised’ reactions Back pain 3

3

D. ‘Other recognised’ reactions Decreased appetite 3

3

D. ‘Other recognised’ reactions Diarrhoea 3

3

D. ‘Other recognised’ reactions Lower respiratory tract infection 3

3

D. ‘Other recognised’ reactions Muscle fatigue 3

3

D. ‘Other recognised’ reactions Muscular weakness 3

3

D. ‘Other recognised’ reactions Rash generalised 3

3

D. ‘Other recognised’ reactions Somnolence 3

3

D. ‘Other recognised’ reactions Cold sweat 2

2

D. ‘Other recognised’ reactions Dizziness postural 2

2

D. ‘Other recognised’ reactions Feeling abnormal 2

2

D. ‘Other recognised’ reactions Gait disturbance 2

2

D. ‘Other recognised’ reactions Head discomfort 2

2

D. ‘Other recognised’ reactions Hot flush 2

2

D. ‘Other recognised’ reactions Influenza like illness 2

2

D. ‘Other recognised’ reactions Joint swelling 2

2

D. ‘Other recognised’ reactions Limb discomfort 2

2

D. ‘Other recognised’ reactions Listless 2

2

D. ‘Other recognised’ reactions Local reaction 2

2

D. ‘Other recognised’ reactions Musculoskeletal stiffness 2

2

D. ‘Other recognised’ reactions Nasal congestion 2

2

D. ‘Other recognised’ reactions Oropharyngeal pain 2

2

D. ‘Other recognised’ reactions Pain 2

2

D. ‘Other recognised’ reactions Pruritus generalised 2

2

D. ‘Other recognised’ reactions Rash macular 2

2

D. ‘Other recognised’ reactions Skin warm 2

2

D. ‘Other recognised’ reactions Throat irritation 2

2

D. ‘Other recognised’ reactions Abdominal pain lower 1

1

D. ‘Other recognised’ reactions Abdominal pain lower 1

1

D. ‘Other recognised’ reactions Arthralgia 1

1

D. ‘Other recognised’ reactions Axillary mass 1

1

D. ‘Other recognised’ reactions Bedridden 1

1

D. ‘Other recognised’ reactions Body temperature 1

1

D. ‘Other recognised’ reactions Body temperature fluctuation 1

1

D. ‘Other recognised’ reactions Body temperature fluctuation 1

1

D. ‘Other recognised’ reactions Cough 1

1

D. ‘Other recognised’ reactions Dyspnoea 1

1

D. ‘Other recognised’ reactions Feeling of body temperature change 1

1

D. ‘Other recognised’ reactions Gastrointestinal disorder 1

1

D. ‘Other recognised’ reactions Generalised erythema 1

1

D. ‘Other recognised’ reactions Groin pain 1

1

D. ‘Other recognised’ reactions Hot flush 1

1

D. ‘Other recognised’ reactions Hypoaesthesia 1

1

D. ‘Other recognised’ reactions Hypotension 1

1

D. ‘Other recognised’ reactions Ill-defined disorder 1

1

D. ‘Other recognised’ reactions Immunisation reaction 1

1

D. ‘Other recognised’ reactions Induration 1

1

D. ‘Other recognised’ reactions Insomnia 1

1

D. ‘Other recognised’ reactions Limb discomfort 1

1

D. ‘Other recognised’ reactions Local reaction 1

1

D. ‘Other recognised’ reactions Local swelling 1

1

D. ‘Other recognised’ reactions Loss of consciousness 1

1

D. ‘Other recognised’ reactions Lymphadenopathy 1

1

D. ‘Other recognised’ reactions Mobility decreased 1

1

D. ‘Other recognised’ reactions Muscle spasms 1

1

D. ‘Other recognised’ reactions Muscle twitching 1

1

D. ‘Other recognised’ reactions Musculoskeletal chest pain 1

1

D. ‘Other recognised’ reactions Musculoskeletal discomfort 1

1

D. ‘Other recognised’ reactions Musculoskeletal discomfort 1

1

D. ‘Other recognised’ reactions Musculoskeletal pain 1

1

D. ‘Other recognised’ reactions Neck pain 1

1

D. ‘Other recognised’ reactions Night sweats 1

1

D. ‘Other recognised’ reactions Pain in extremity 1

1

D. ‘Other recognised’ reactions Peripheral coldness 1

1

D. ‘Other recognised’ reactions Pharyngitis 1

1

D. ‘Other recognised’ reactions Rash erythematous 1

1

D. ‘Other recognised’ reactions Respiratory disorder 1

1

D. ‘Other recognised’ reactions Respiratory tract infection 1

1

D. ‘Other recognised’ reactions Restlessness 1

1

D. ‘Other recognised’ reactions Rhinorrhoea 1

1

D. ‘Other recognised’ reactions Sensation of heaviness 1

1

D. ‘Other recognised’ reactions Sudden onset of sleep 1

1

D. ‘Other recognised’ reactions Swelling 1

1

D. ‘Other recognised’ reactions Swelling face 1

1

D. ‘Other recognised’ reactions Syncope 1

1

D. ‘Other recognised’ reactions Thirst 1

1

D. ‘Other recognised’ reactions Throat tightness 1

1

D. ‘Other recognised’ reactions Upper respiratory tract infection 1

1

D. ‘Other recognised’ reactions Urticaria 1

1

D. ‘Other recognised’ reactions Weight decreased 1

1

Nervous system disorders E. not currently recognised Headache 47

47

Nervous system disorders E. not currently recognised Syncope 35

35

General disorders and administration site conditions E. not currently recognised Influenza like illness 32

32

Nervous system disorders E. not currently recognised Dizziness 29

29

Nervous system disorders E. not currently recognised Hypoaesthesia 29

29

Nervous system disorders E. not currently recognised Convulsion 28

28

Musculoskeletal and connective tissue disorders E. not currently recognised Pain in extremity 27

27

Gastrointestinal disorders E. not currently recognised Nausea 24

24

Nervous system disorders E. not currently recognised Paraesthesia 20

20

Respiratory, thoracic and mediastinal disorders E. not currently recognised Dyspnoea 19

19

Nervous system disorders E. not currently recognised Lethargy 19

19

General disorders and administration site conditions E. not currently recognised Malaise 19

19

Injury, poisoning and procedural complications E. not currently recognised Drug exposure during pregnancy 18

18

General disorders and administration site conditions E. not currently recognised Fatigue 18

18

General disorders and administration site conditions E. not currently recognised Pyrexia 18

18

General disorders and administration site conditions E. not currently recognised Chest pain 17

17

Gastrointestinal disorders E. not currently recognised Vomiting 17

17

Nervous system disorders E. not currently recognised Migraine 16

16

General disorders and administration site conditions E. not currently recognised Pain 16

16

Musculoskeletal and connective tissue disorders E. not currently recognised Back pain 15

15

Nervous system disorders E. not currently recognised Somnolence 14

14

Nervous system disorders E. not currently recognised Tremor 14

14

Nervous system disorders E. not currently recognised Dizziness 12

12

Musculoskeletal and connective tissue disorders E. not currently recognised Muscular weakness 12

12

Pregnancy, puerperium and perinatal conditions E. not currently recognised Abortion spontaneous 11

11

General disorders and administration site conditions E. not currently recognised Asthenia 11

11

Nervous system disorders E. not currently recognised Headache 11

11

Nervous system disorders E. not currently recognised Loss of consciousness 11

11

Gastrointestinal disorders E. not currently recognised Abdominal pain 10

10

Musculoskeletal and connective tissue disorders E. not currently recognised Myalgia 10

10

Respiratory, thoracic and mediastinal disorders E. not currently recognised Oropharyngeal pain 10

10

Reproductive system and breast disorders E. not currently recognised Amenorrhoea 9

9

General disorders and administration site conditions E. not currently recognised Chest discomfort 9

9

Vascular disorders E. not currently recognised Peripheral coldness 9

9

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia 8

8

Respiratory, thoracic and mediastinal disorders E. not currently recognised Cough 8

8

Metabolism and nutrition disorders E. not currently recognised Decreased appetite 8

8

Respiratory, thoracic and mediastinal disorders E. not currently recognised Epistaxis 8

8

General disorders and administration site conditions E. not currently recognised Fatigue 8

8

General disorders and administration site conditions E. not currently recognised Influenza like illness 8

8

Eye disorders E. not currently recognised Vision blurred 8

8

Respiratory, thoracic and mediastinal disorders E. not currently recognised Asthma 7

7

Gastrointestinal disorders E. not currently recognised Diarrhoea 7

7

General disorders and administration site conditions E. not currently recognised Feeling cold 7

7

Nervous system disorders E. not currently recognised Hypoaesthesia 7

7

Skin and subcutaneous tissue disorders E. not currently recognised Hypoaesthesia facial 7

7

Eye disorders E. not currently recognised Photophobia 7

7

Nervous system disorders E. not currently recognised Syncope 7

7

Reproductive system and breast disorders E. not currently recognised Vaginal haemorrhage 7

7

Infections and infestations E. not currently recognised Viral infection 7

7

Eye disorders E. not currently recognised Vision blurred 7

7

Gastrointestinal disorders E. not currently recognised Abdominal pain 6

6

Nervous system disorders E. not currently recognised Dysarthria 6

6

Ear and labyrinth disorders E. not currently recognised Ear pain 6

6

Nervous system disorders E. not currently recognised Epilepsy 6

6

Psychiatric disorders E. not currently recognised Hallucination 6

6

Psychiatric disorders E. not currently recognised Insomnia 6

6

Infections and infestations E. not currently recognised Lower respiratory tract infection 6

6

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal stiffness 6

6

Musculoskeletal and connective tissue disorders E. not currently recognised Neck pain 6

6

Cardiac disorders E. not currently recognised Palpitations 6

6

Nervous system disorders E. not currently recognised Paraesthesia 6

6

Infections and infestations E. not currently recognised Post viral fatigue syndrome 6

6

Nervous system disorders E. not currently recognised Sensory disturbance 6

6

Eye disorders E. not currently recognised Visual impairment 6

6

General disorders and administration site conditions E. not currently recognised Abasia 5

5

Nervous system disorders E. not currently recognised Dyskinesia 5

5

Nervous system disorders E. not currently recognised Dysstasia 5

5

Skin and subcutaneous tissue disorders E. not currently recognised Eczema 5

5

Skin and subcutaneous tissue disorders E. not currently recognised Erythema multiforme 5

5

Nervous system disorders E. not currently recognised Facial palsy 5

5

Nervous system disorders E. not currently recognised Grand mal convulsion 5

5

Reproductive system and breast disorders E. not currently recognised Menstruation irregular 5

5

General disorders and administration site conditions E. not currently recognised Oedema peripheral 5

5

Vascular disorders E. not currently recognised Pallor 5

5

Musculoskeletal and connective tissue disorders E. not currently recognised Sensation of heaviness 5

5

Investigations E. not currently recognised Weight decreased 5

5

Psychiatric disorders E. not currently recognised Anxiety 4

4

Musculoskeletal and connective tissue disorders E. not currently recognised Arthralgia 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Blister 4

4

Investigations E. not currently recognised Blood glucose increased 4

4

General disorders and administration site conditions E. not currently recognised Chills 4

4

General disorders and administration site conditions E. not currently recognised Chronic fatigue syndrome 4

4

General disorders and administration site conditions E. not currently recognised Condition aggravated 4

4

Psychiatric disorders E. not currently recognised Confusional state 4

4

Injury, poisoning and procedural complications E. not currently recognised Contusion 4

4

Cardiac disorders E. not currently recognised Cyanosis 4

4

Reproductive system and breast disorders E. not currently recognised Dysmenorrhoea 4

4

Nervous system disorders E. not currently recognised Encephalitis 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Erythema 4

4

General disorders and administration site conditions E. not currently recognised Feeling hot 4

4

Nervous system disorders E. not currently recognised Guillain-barre syndrome 4

4

Vascular disorders E. not currently recognised Hypotension 4

4

Nervous system disorders E. not currently recognised Lethargy 4

4

Reproductive system and breast disorders E. not currently recognised Menorrhagia 4

4

Infections and infestations E. not currently recognised Nasopharyngitis 4

4

Gastrointestinal disorders E. not currently recognised Nausea 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Rash 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Rash 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Skin discolouration 4

4

Respiratory, thoracic and mediastinal disorders E. not currently recognised Wheezing 4

4

Surgical and medical procedures E. not currently recognised Abortion induced 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia 3

3

Nervous system disorders E. not currently recognised Aphonia 3

3

Nervous system disorders E. not currently recognised Convulsion 3

3

Psychiatric disorders E. not currently recognised Disorientation 3

3

Ear and labyrinth disorders E. not currently recognised Ear pain 3

3

Nervous system disorders E. not currently recognised Epilepsy 3

3

General disorders and administration site conditions E. not currently recognised Feeling abnormal 3

3

Nervous system disorders E. not currently recognised Head discomfort 3

3

Nervous system disorders E. not currently recognised Hemiparesis 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Hyperhidrosis 3

3

Infections and infestations E. not currently recognised Infectious mononucleosis 3

3

Pregnancy, puerperium and perinatal conditions E. not currently recognised Live birth 3

3

Reproductive system and breast disorders E. not currently recognised Menstruation delayed 3

3

Gastrointestinal disorders E. not currently recognised Mouth ulceration 3

3

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle twitching 3

3

Eye disorders E. not currently recognised Mydriasis 3

3

Vascular disorders E. not currently recognised Peripheral coldness 3

3

Pregnancy, puerperium and perinatal conditions E. not currently recognised Premature baby 3

3

General disorders and administration site conditions E. not currently recognised Pyrexia 3

3

Nervous system disorders E. not currently recognised Sensory loss 3

3

Psychiatric disorders E. not currently recognised Tearfulness 3

3

Nervous system disorders E. not currently recognised Tremor 3

3

Nervous system disorders E. not currently recognised Unresponsive to stimuli 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Urticaria 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Urticaria chronic 3

3

Nervous system disorders E. not currently recognised Visual field defect 3

3

General disorders and administration site conditions E. not currently recognised Abasia 2

2

Gastrointestinal disorders E. not currently recognised Abdominal pain upper 2

2

Psychiatric disorders E. not currently recognised Abnormal behaviour 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia areata 2

2

Reproductive system and breast disorders E. not currently recognised Amenorrhoea 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Angioedema 2

2

Nervous system disorders E. not currently recognised Balance disorder 2

2

Investigations E. not currently recognised Body temperature increased 2

2

Vascular disorders E. not currently recognised Circulatory collapse 2

2

Nervous system disorders E. not currently recognised Complex regional pain syndrome 2

2

Nervous system disorders E. not currently recognised Complex regional pain syndrome 2

2

Psychiatric disorders E. not currently recognised Confusional state 2

2

Nervous system disorders E. not currently recognised Crying 2

2

Metabolism and nutrition disorders E. not currently recognised Dehydration 2

2

Psychiatric disorders E. not currently recognised Depressed mood 2

2

Nervous system disorders E. not currently recognised Diplegia 2

2

Eye disorders E. not currently recognised Diplopia 2

2

Nervous system disorders E. not currently recognised Disturbance in attention 2

2

Nervous system disorders E. not currently recognised Dizziness postural 2

2

Nervous system disorders E. not currently recognised Drooling 2

2

Injury, poisoning and procedural complications E. not currently recognised Drug exposure before pregnancy 2

2

Nervous system disorders E. not currently recognised Dysgeusia 2

2

Psychiatric disorders E. not currently recognised Emotional disorder 2

2

Eye disorders E. not currently recognised Eye pain 2

2

Nervous system disorders E. not currently recognised Facial paresis 2

2

General disorders and administration site conditions E. not currently recognised Feeling cold 2

2

General disorders and administration site conditions E. not currently recognised Gait disturbance 2

2

General disorders and administration site conditions E. not currently recognised Gait disturbance 2

2

Nervous system disorders E. not currently recognised Grand mal convulsion 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Groin pain 2

2

Respiratory, thoracic and mediastinal disorders E. not currently recognised Haemoptysis 2

2

Vascular disorders E. not currently recognised Haemorrhage 2

2

Infections and infestations E. not currently recognised Herpes zoster 2

2

Infections and infestations E. not currently recognised Hordeolum 2

2

Vascular disorders E. not currently recognised Hot flush 2

2

Respiratory, thoracic and mediastinal disorders E. not currently recognised Hyperventilation 2

2

Nervous system disorders E. not currently recognised Hypokinesia 2

2

Infections and infestations E. not currently recognised Influenza 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Joint swelling 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Livedo reticularis 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Livedo reticularis 2

2

General disorders and administration site conditions E. not currently recognised Local swelling 2

2

Nervous system disorders E. not currently recognised Loss of consciousness 2

2

General disorders and administration site conditions E. not currently recognised Malaise 2

2

Reproductive system and breast disorders E. not currently recognised Menstrual disorder 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Mobility decreased 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle spasms 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Muscular weakness 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal pain 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal stiffness 2

2

Nervous system disorders E. not currently recognised Optic neuritis 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Pain in extremity 2

2

Vascular disorders E. not currently recognised Pallor 2

2

Gastrointestinal disorders E. not currently recognised Paraesthesia oral 2

2

Nervous system disorders E. not currently recognised Petit mal epilepsy 2

2

Infections and infestations E. not currently recognised Pharyngitis 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Photosensitivity reaction 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Photosensitivity reaction 2

2

Congenital, familial and genetic disorders E. not currently recognised Pilonidal cyst congenital 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Purpura 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Rash generalised 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Rheumatoid arthritis 2

2

Respiratory, thoracic and mediastinal disorders E. not currently recognised Rhinorrhoea 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Skin exfoliation 2

2

Psychiatric disorders E. not currently recognised Sleep disorder 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Swelling face 2

2

Cardiac disorders E. not currently recognised Tachycardia 2

2

Renal and urinary disorders E. not currently recognised Urinary incontinence 2

2

Renal and urinary disorders E. not currently recognised Urinary retention 2

2

Infections and infestations E. not currently recognised Urinary tract infection 2

2

Ear and labyrinth disorders E. not currently recognised Vertigo 2

2

Eye disorders E. not currently recognised Visual impairment 2

2

Reproductive system and breast disorders E. not currently recognised Vulval ulceration 2

2

Investigations E. not currently recognised Weight increased 2

2

Gastrointestinal disorders E. not currently recognised Abdominal discomfort 1

1

Gastrointestinal disorders E. not currently recognised Abdominal discomfort 1

1

Gastrointestinal disorders E. not currently recognised Abdominal pain lower 1

1

Gastrointestinal disorders E. not currently recognised Abdominal pain upper 1

1

Gastrointestinal disorders E. not currently recognised Abnormal faeces 1

1

Psychiatric disorders E. not currently recognised Abnormal sleep-related event 1

1

Infections and infestations E. not currently recognised Abscess 1

1

Infections and infestations E. not currently recognised Acarodermatitis 1

1

Eye disorders E. not currently recognised Accommodation disorder 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Acne 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Acne 1

1

Neoplasms benign, malignant and unspecified (incl cysts and polyps) E. not currently recognised Acute myeloid leukaemia 1

1

Psychiatric disorders E. not currently recognised Acute psychosis 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Acute respiratory failure 1

1

Endocrine disorders E. not currently recognised Adrenocortical insufficiency acute 1

1

Endocrine disorders E. not currently recognised Adrenocortical insufficiency acute 1

1

Psychiatric disorders E. not currently recognised Aggression 1

1

Investigations E. not currently recognised Alanine aminotransferase increased 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia areata 1

1

Blood and lymphatic system disorders E. not currently recognised Anaemia 1

1

Infections and infestations E. not currently recognised Anogenital warts 1

1

Nervous system disorders E. not currently recognised Aphasia 1

1

Blood and lymphatic system disorders E. not currently recognised Aplastic anaemia 1

1

Infections and infestations E. not currently recognised Application site pustules 1

1

Nervous system disorders E. not currently recognised Areflexia 1

1

Congenital, familial and genetic disorders E. not currently recognised Arteriovenous malformation 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Arthritis 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Arthritis reactive 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Arthropathy 1

1

General disorders and administration site conditions E. not currently recognised Asthenia 1

1

Nervous system disorders E. not currently recognised Ataxia 1

1

Injury, poisoning and procedural complications E. not currently recognised Axillary nerve injury 1

1

General disorders and administration site conditions E. not currently recognised Axillary pain 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Back pain 1

1

Nervous system disorders E. not currently recognised Balance disorder 1

1

Neoplasms benign, malignant and unspecified (incl cysts and polyps) E. not currently recognised Benign hydatidiform mole 1

1

Infections and infestations E. not currently recognised Beta haemolytic streptococcal infection 1

1

Eye disorders E. not currently recognised Blindness unilateral 1

1

Investigations E. not currently recognised Blood cortisol decreased 1

1

Investigations E. not currently recognised Blood pressure decreased 1

1

Investigations E. not currently recognised Blood pressure increased 1

1

Investigations E. not currently recognised Body temperature increased 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Bone pain 1

1

Reproductive system and breast disorders E. not currently recognised Breast pain 1

1

Reproductive system and breast disorders E. not currently recognised Breast swelling 1

1

Reproductive system and breast disorders E. not currently recognised Breast tenderness 1

1

Infections and infestations E. not currently recognised Bronchitis 1

1

Nervous system disorders E. not currently recognised Burning sensation 1

1

Cardiac disorders E. not currently recognised Cardiac arrest 1

1

Investigations E. not currently recognised Cell marker increased 1

1

Congenital, familial and genetic disorders E. not currently recognised Cerebral palsy 1

1

Reproductive system and breast disorders E. not currently recognised Cervix inflammation 1

1

General disorders and administration site conditions E. not currently recognised Chest discomfort 1

1

General disorders and administration site conditions E. not currently recognised Chest pain 1

1

General disorders and administration site conditions E. not currently recognised Chills 1

1

Nervous system disorders E. not currently recognised Chorea 1

1

Congenital, familial and genetic disorders E. not currently recognised Cleft palate 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Cold sweat 1

1

Gastrointestinal disorders E. not currently recognised Colitis 1

1

Gastrointestinal disorders E. not currently recognised Colitis ulcerative 1

1

General disorders and administration site conditions E. not currently recognised Condition aggravated 1

1

Eye disorders E. not currently recognised Conjunctival hyperaemia 1

1

Gastrointestinal disorders E. not currently recognised Constipation 1

1

Nervous system disorders E. not currently recognised Coordination abnormal 1

1

Investigations E. not currently recognised Csf cell count increased 1

1

Eye disorders E. not currently recognised Dark circles under eyes 1

1

Ear and labyrinth disorders E. not currently recognised Deafness 1

1

Ear and labyrinth disorders E. not currently recognised Deafness bilateral 1

1

Metabolism and nutrition disorders E. not currently recognised Decreased appetite 1

1

Psychiatric disorders E. not currently recognised Decreased interest 1

1

Vascular disorders E. not currently recognised Deep vein thrombosis 1

1

Nervous system disorders E. not currently recognised Depressed level of consciousness 1

1

Psychiatric disorders E. not currently recognised Depression 1

1

Psychiatric disorders E. not currently recognised Depression 1

1

Psychiatric disorders E. not currently recognised Depressive symptom 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Dermatitis allergic 1

1

Metabolism and nutrition disorders E. not currently recognised Diabetes mellitus inadequate control 1

1

Metabolism and nutrition disorders E. not currently recognised Diabetes mellitus inadequate control 1

1

Metabolism and nutrition disorders E. not currently recognised Diabetic ketoacidosis 1

1

Gastrointestinal disorders E. not currently recognised Diarrhoea 1

1

Gastrointestinal disorders E. not currently recognised Diarrhoea haemorrhagic 1

1

General disorders and administration site conditions E. not currently recognised Discomfort 1

1

Psychiatric disorders E. not currently recognised Dissociation 1

1

Nervous system disorders E. not currently recognised Dizziness postural 1

1

Eye disorders E. not currently recognised Dry eye 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Dry skin 1

1

Nervous system disorders E. not currently recognised Dysgeusia 1

1

Nervous system disorders E. not currently recognised Dyskinesia 1

1

Psychiatric disorders E. not currently recognised Dysphemia 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Dyspnoea 1

1

Ear and labyrinth disorders E. not currently recognised Ear discomfort 1

1

Psychiatric disorders E. not currently recognised Eating disorder 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Eczema vesicular 1

1

Psychiatric disorders E. not currently recognised Emotional distress 1

1

Nervous system disorders E. not currently recognised Encephalitis 1

1

Blood and lymphatic system disorders E. not currently recognised Eosinophilia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Erythema 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Erythema multiforme 1

1

Eye disorders E. not currently recognised Excessive eye blinking 1

1

General disorders and administration site conditions E. not currently recognised Exercise tolerance decreased 1

1

Eye disorders E. not currently recognised Eye discharge 1

1

Eye disorders E. not currently recognised Eye disorder 1

1

Eye disorders E. not currently recognised Eye pain 1

1

Eye disorders E. not currently recognised Eye swelling 1

1

Eye disorders E. not currently recognised Eyelid oedema 1

1

Nervous system disorders E. not currently recognised Facial palsy 1

1

Injury, poisoning and procedural complications E. not currently recognised Fall 1

1

Psychiatric disorders E. not currently recognised Fear 1

1

General disorders and administration site conditions E. not currently recognised Feeling abnormal 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Flank pain 1

1

Gastrointestinal disorders E. not currently recognised Flatulence 1

1

Vascular disorders E. not currently recognised Flushing 1

1

Infections and infestations E. not currently recognised Folliculitis 1

1

Gastrointestinal disorders E. not currently recognised Frequent bowel movements 1

1

Infections and infestations E. not currently recognised Furuncle 1

1

Gastrointestinal disorders E. not currently recognised Gastrointestinal disorder 1

1

Eye disorders E. not currently recognised Gaze palsy 1

1

Gastrointestinal disorders E. not currently recognised Gingival disorder 1

1

Nervous system disorders E. not currently recognised Guillain-barre syndrome 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Guttate psoriasis 1

1

Blood and lymphatic system disorders E. not currently recognised Haemolytic uraemic syndrome 1

1

Psychiatric disorders E. not currently recognised Hallucination, auditory 1

1

Psychiatric disorders E. not currently recognised Hallucination, visual 1

1

Congenital, familial and genetic disorders E. not currently recognised Heart disease congenital 1

1

Investigations E. not currently recognised Heart rate decreased 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Henoch-schonlein purpura 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Henoch-schonlein purpura 1

1

Infections and infestations E. not currently recognised Hepatitis viral 1

1

Infections and infestations E. not currently recognised Herpes zoster 1

1

Ear and labyrinth disorders E. not currently recognised Hyperacusis 1

1

Metabolism and nutrition disorders E. not currently recognised Hyperglycaemia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Hyperhidrosis 1

1

General disorders and administration site conditions E. not currently recognised Hyperpyrexia 1

1

Immune system disorders E. not currently recognised Hypersensitivity 1

1

Nervous system disorders E. not currently recognised Hypertonia 1

1

Ear and labyrinth disorders E. not currently recognised Hypoacusis 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Hypoaesthesia facial 1

1

Gastrointestinal disorders E. not currently recognised Hypoaesthesia oral 1

1

Metabolism and nutrition disorders E. not currently recognised Hypoglycaemia 1

1

Psychiatric disorders E. not currently recognised Hypomania 1

1

Congenital, familial and genetic disorders E. not currently recognised Hypospadias 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Hypoventilation 1

1

Injury, poisoning and procedural complications E. not currently recognised Inappropriate schedule of drug administration 1

1

Injury, poisoning and procedural complications E. not currently recognised Incorrect dose administered 1

1

Metabolism and nutrition disorders E. not currently recognised Increased appetite 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Increased upper airway secretion 1

1

Infections and infestations E. not currently recognised Infection 1

1

General disorders and administration site conditions E. not currently recognised Inflammation 1

1

General disorders and administration site conditions E. not currently recognised Injection site erythema 1

1

General disorders and administration site conditions E. not currently recognised Injection site injury 1

1

General disorders and administration site conditions E. not currently recognised Injection site swelling 1

1

Psychiatric disorders E. not currently recognised Insomnia 1

1

Gastrointestinal disorders E. not currently recognised Intestinal functional disorder 1

1

Gastrointestinal disorders E. not currently recognised Irritable bowel syndrome 1

1

Nervous system disorders E. not currently recognised Ivth nerve paralysis 1

1

Hepatobiliary disorders E. not currently recognised Jaundice 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Joint stiffness 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Joint stiffness 1

1

Infections and infestations E. not currently recognised Kidney infection 1

1

Infections and infestations E. not currently recognised Labyrinthitis 1

1

Infections and infestations E. not currently recognised Laryngitis 1

1

Congenital, familial and genetic disorders E. not currently recognised Limb malformation 1

1

Gastrointestinal disorders E. not currently recognised Lip blister 1

1

Gastrointestinal disorders E. not currently recognised Lip swelling 1

1

General disorders and administration site conditions E. not currently recognised Local swelling 1

1

Nervous system disorders E. not currently recognised Meningism 1

1

Reproductive system and breast disorders E. not currently recognised Menorrhagia 1

1

Reproductive system and breast disorders E. not currently recognised Menstrual disorder 1

1

Reproductive system and breast disorders E. not currently recognised Menstruation delayed 1

1

Reproductive system and breast disorders E. not currently recognised Menstruation irregular 1

1

Reproductive system and breast disorders E. not currently recognised Metrorrhagia 1

1

Nervous system disorders E. not currently recognised Migraine 1

1

Nervous system disorders E. not currently recognised Migraine with aura 1

1

Infections and infestations E. not currently recognised Molluscum contagiosum 1

1

Nervous system disorders E. not currently recognised Monoplegia 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle rigidity 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle twitching 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal chest pain 1

1

Nervous system disorders E. not currently recognised Myoclonic epilepsy 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Nasal congestion 1

1

Neoplasms benign, malignant and unspecified (incl cysts and polyps) E. not currently recognised Neoplasm malignant 1

1

Nervous system disorders E. not currently recognised Neuritis 1

1

Renal and urinary disorders E. not currently recognised Neurogenic bladder 1

1

Blood and lymphatic system disorders E. not currently recognised Neutropenia 1

1

Investigations E. not currently recognised Neutrophil count decreased 1

1

General disorders and administration site conditions E. not currently recognised Oedema peripheral 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Oropharyngeal blistering 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Oropharyngeal pain 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Osteitis 1

1

Infections and infestations E. not currently recognised Otitis media 1

1

General disorders and administration site conditions E. not currently recognised Pain 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Palindromic rheumatism 1

1

Blood and lymphatic system disorders E. not currently recognised Pancytopenia 1

1

Nervous system disorders E. not currently recognised Paralysis 1

1

Psychiatric disorders E. not currently recognised Paranoia 1

1

Investigations E. not currently recognised Peak expiratory flow rate decreased 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Petechiae 1

1

Eye disorders E. not currently recognised Photopsia 1

1

Investigations E. not currently recognised Platelet count decreased 1

1

Infections and infestations E. not currently recognised Pneumonia viral 1

1

Renal and urinary disorders E. not currently recognised Pollakiuria 1

1

Pregnancy, puerperium and perinatal conditions E. not currently recognised Pregnancy with injectable contraceptive 1

1

Nervous system disorders E. not currently recognised Presyncope 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Productive cough 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Psoriasis 1

1

Psychiatric disorders E. not currently recognised Psychiatric symptom 1

1

Nervous system disorders E. not currently recognised Psychomotor hyperactivity 1

1

Psychiatric disorders E. not currently recognised Psychotic disorder 1

1

Investigations E. not currently recognised Radial pulse 1

1

Nervous system disorders E. not currently recognised Radiculitis brachial 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Rash erythematous 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Rash maculo-papular 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Rash vesicular 1

1

Renal and urinary disorders E. not currently recognised Renal failure 1

1

Investigations E. not currently recognised Respiratory rate increased 1

1

Infections and infestations E. not currently recognised Respiratory syncytial virus infection 1

1

Infections and infestations E. not currently recognised Respiratory tract infection 1

1

Psychiatric disorders E. not currently recognised Screaming 1

1

Nervous system disorders E. not currently recognised Sedation 1

1

General disorders and administration site conditions E. not currently recognised Sensation of foreign body 1

1

General disorders and administration site conditions E. not currently recognised Sensation of pressure 1

1

Nervous system disorders E. not currently recognised Sensory loss 1

1

Infections and infestations E. not currently recognised Sepsis 1

1

Infections and infestations E. not currently recognised Severe acute respiratory syndrome 1

1

Cardiac disorders E. not currently recognised Sinus tachycardia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin burning sensation 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin disorder 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin hypertrophy 1

1

Infections and infestations E. not currently recognised Skin infection 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin irritation 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin lesion 1

1

Psychiatric disorders E. not currently recognised Somatisation disorder 1

1

Nervous system disorders E. not currently recognised Somnolence 1

1

Nervous system disorders E. not currently recognised Speech disorder 1

1

Infections and infestations E. not currently recognised Staphylococcal infection 1

1

Nervous system disorders E. not currently recognised Status epilepticus 1

1

Infections and infestations E. not currently recognised Streptococcal sepsis 1

1

General disorders and administration site conditions E. not currently recognised Swelling 1

1

Gastrointestinal disorders E. not currently recognised Swollen tongue 1

1

General disorders and administration site conditions E. not currently recognised Systemic inflammatory response syndrome 1

1

General disorders and administration site conditions E. not currently recognised Temperature intolerance 1

1

General disorders and administration site conditions E. not currently recognised Tenderness 1

1

General disorders and administration site conditions E. not currently recognised Thirst 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Throat tightness 1

1

Ear and labyrinth disorders E. not currently recognised Tinnitus 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Trichorrhexis 1

1

Metabolism and nutrition disorders E. not currently recognised Type 1 diabetes mellitus 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Upper airway obstruction 1

1

Infections and infestations E. not currently recognised Upper respiratory tract infection 1

1

Renal and urinary disorders E. not currently recognised Urinary retention 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Urticaria 1

1

Reproductive system and breast disorders E. not currently recognised Vaginal discharge 1

1

Reproductive system and breast disorders E. not currently recognised Vaginal lesion 1

1

Infections and infestations E. not currently recognised Varicella 1

1

Infections and infestations E. not currently recognised Viraemia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Vitiligo 1

1

Eye disorders E. not currently recognised Vitreous floaters 1

1

Gastrointestinal disorders E. not currently recognised Vomiting 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Weight bearing difficulty 1

1

Investigations E. not currently recognised Weight decreased 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Wheezing 1

1

Injury, poisoning and procedural complications E. not currently recognised Wrong technique in drug usage process 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Yellow skin 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Stevens-johnson syndrome 1  1

Japanese girls will still be able to be vaccinated at no charge, but from now on they will be informed by healthcare providers that the health ministry does not recommend the vaccines. 

Medicines and Healthcare Products Regulatory Agency [

About these ads

10 Responses

  1. Reblogged this on News-Press.

  2. Regarding encephalitis at the moment believe there are six cases reported by the MHRA for Cervarix but what they do not tell you is that three of these cases at least are the autoimmune encephalitis – anti-NMDA receptor encephalitis which is not common, not population related. They do not want the public to know this and prefer to lump them altogether under viral encephalitis – you are correct that is falsyfing the records.

  3. Reblogged this on News You May Have Missed and commented:
    WORLD EXCLUSIVE – UK Drug Safety Agency Falsified Vaccine Safety Data For 6 Million – Millions of Children At Serious Risk

  4. […] Bullshitting about the HPV vaccine. Here is Child Health Safety scaremongering and lying about the HPV vaccine, cervical cancer and the collection of adverse events reports. […]

  5. This is nothing less than evil. (“UK health officials tampered with vaccine adverse event reporting systems.”

  6. […] International medical researchers issue warning about HPV Vaccine side effects [3] UK Drug Safety Agency falsified Vaccine Safety Data for 6 million [4] A. P. Fletcher, “Spontaneous adverse drug reaction reporting vs event monitoring: a […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 1,037 other followers

%d bloggers like this: